Search

Your search keyword '"Tozuka, Yuichiro"' showing total 23 results
Start Over Author "Tozuka, Yuichiro"
23 results on '"Tozuka, Yuichiro"'

7. A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer

Author

Kobayashi, Satoshi, Ueno, Makoto, Ikeda, Masafumi, Ozaka, Masato, Sano, Yusuke, Hirotani, Akane, Tozuka, Yuichiro, Fukushima, Taito, Tezuka, Shun, Moriya, Satoshi, Umemoto, Kumiko, Watanabe, Kazuo, Sasaki, Mitsuhito, Hashimoto, Yusuke, Imaoka, Hiroshi, Ohno, Izumi, Mitsunaga, Shuichi, Yamada, Ikuhiro, Sasaki, Takashi, Sasahira, Naoki, and Morimoto, Manabu

Published
2020
Full Text
View/download PDF

8. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: A retrospective observational study

Author

Kobayashi, Satoshi, primary, Tezuka, Shun, additional, Yamachika, Yui, additional, Tsunoda, Shotaro, additional, Nagashima, Shuhei, additional, Tozuka, Yuichiro, additional, Fukushima, Taito, additional, Morimoto, Manabu, additional, Ueno, Makoto, additional, Furuse, Junji, additional, and Maeda, Shin, additional

Published
2022
Full Text
View/download PDF

10. Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab‑paclitaxel: A retrospective study

Author

Tozuka, Yuichiro, primary, Ueno, Makoto, additional, Kobayashi, Satoshi, additional, Morimoto, Manabu, additional, Fukushima, Taito, additional, Sano, Yusuke, additional, Kawano, Kuniyuki, additional, Hanaoka, Akane, additional, Tezuka, Shun, additional, Asama, Hiroyuki, additional, Moriya, Satoshi, additional, Morinaga, Soichiro, additional, Ohkawa, Shinichi, additional, and Maeda, Shin, additional

Published
2022
Full Text
View/download PDF

12. Multiple-line Chemotherapy for a Patient with Unresectable Mucinous Cystic Neoplasm of the Pancreas

Author

Miwa, Haruo, primary, Sugimori, Kazuya, additional, Ishii, Tomohiro, additional, Funaoka, Akihiro, additional, Tsuchiya, Hiromi, additional, Suzuki, Yoshimasa, additional, Sugimori, Makoto, additional, Nishimura, Masaki, additional, Tozuka, Yuichiro, additional, Komiyama, Satoshi, additional, Sato, Takeshi, additional, Kaneko, Takashi, additional, Numata, Kazushi, additional, and Maeda, Shin, additional

Published
2021
Full Text
View/download PDF

14. Clinical outcome of a highly flexible duodenal stent for gastric outlet obstruction: A multicenter prospective study

Author

Miwa, Haruo, primary, Sugimori, Kazuya, additional, Kaneko, Takashi, additional, Ishii, Tomohiro, additional, Iwase, Shigeru, additional, Irie, Kuniyasu, additional, Sanga, Katsuyuki, additional, Tozuka, Yuichiro, additional, Hirotani, Akane, additional, Komiyama, Satoshi, additional, Sato, Takeshi, additional, Tezuka, Shun, additional, Goda, Yoshihiro, additional, Numata, Kazushi, additional, and Maeda, Shin, additional

Published
2020
Full Text
View/download PDF

15. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy

Author

Sugimori, Makoto, primary, Sugimori, Kazuya, additional, Tsuchiya, Hiromi, additional, Suzuki, Yoshimasa, additional, Tsuyuki, Sho, additional, Kaneta, Yoshihiro, additional, Hirotani, Akane, additional, Sanga, Katsuyuki, additional, Tozuka, Yuichiro, additional, Komiyama, Satoshi, additional, Sato, Takeshi, additional, Tezuka, Shun, additional, Goda, Yoshihiro, additional, Irie, Kuniyasu, additional, Miwa, Haruo, additional, Miura, Yuuki, additional, Ishii, Tomohiro, additional, Kaneko, Takashi, additional, Nagahama, Masatsugu, additional, Shibata, Wataru, additional, Nozaki, Akito, additional, and Maeda, Shin, additional

Published
2019
Full Text
View/download PDF

18. Tu1072 CLINICAL OUTCOME OF HIGHLY FLEXIBLE DUODENAL STENT FOR GASTRIC OUTLET OBSTRUCTION: MULTICENTER PROSPECTIVE STUDY

Author

Miwa, Haruo, primary, Sugimori, Kazuya, additional, Kaneko, Takashi, additional, Ishii, Tomohiro, additional, Iwase, Shigeru, additional, Irie, Kuniyasu, additional, Sanga, Katsuyuki, additional, Tozuka, Yuichiro, additional, Hirotani, Akane, additional, Komiyama, Satoshi, additional, Sato, Takeshi, additional, Tezuka, Shun, additional, Goda, Yoshihiro, additional, Numata, Kazushi, additional, and Maeda, Shin, additional

Published
2019
Full Text
View/download PDF

19. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy.

Author

Sugimori, Makoto, Sugimori, Kazuya, Tsuchiya, Hiromi, Suzuki, Yoshimasa, Tsuyuki, Sho, Kaneta, Yoshihiro, Hirotani, Akane, Sanga, Katsuyuki, Tozuka, Yuichiro, Komiyama, Satoshi, Sato, Takeshi, Tezuka, Shun, Goda, Yoshihiro, Irie, Kuniyasu, Miwa, Haruo, Miura, Yuuki, Ishii, Tomohiro, Kaneko, Takashi, Nagahama, Masatsugu, and Shibata, Wataru

Abstract

According to cancer genome sequences, more than 90% of cases of pancreatic ductal adenocarcinoma (PDAC) harbor active KRAS mutations. Digital PCR (dPCR) enables accurate detection and quantification of rare mutations. We assessed the dynamics of circulating tumor DNA (ct‐DNA) in patients with advanced PDAC undergoing chemotherapy using dPCR. KRAS G12/13 mutation was assayed by dPCR in 47 paired tissue‐ and ct‐DNA samples. The 21 patients were subjected to quantitative ct‐DNA monitoring at 4 to 8‐week intervals during chemotherapy. KRAS mutation was detected in 45 of those 47 patients using tissue DNA. In the KRAS mutation‐negative cases, next‐generation sequencing revealed KRAS Q61K and NRAS Q61R mutations. KRAS mutation was detected in 23/45 cases using ct‐DNA (liver or lung metastasis, 18/19; mutation allele frequency [MAF], 0.1%‐31.7%; peritoneal metastasis, 3/9 [0.1%], locally advanced, 2/17 [0.1%‐0.2%]). In the ct‐DNA monitoring, the MAF value changed in concordance with the disease state. In the 6 locally advanced cases, KRAS mutation appeared concurrently with liver metastasis. Among the 6 cases with liver metastasis, KRAS mutation disappeared during the duration of stable disease or a partial response, and reappeared at the time of progressive disease. The median progression‐free survival was longer in cases in which KRAS mutation disappeared after an initial course of chemotherapy than in those in which it was continuously detected (248.5 vs 50 days, P <.001). Therefore, ct‐DNA monitoring enables continuous assessment of disease state and could have prognostic utility during chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

20. A case of anastomotic recurrence after surgery for gastric cancer diagnosed by endoscopic ultrasound-guided fine needle aspiration

Author

Murohashi, Kouta, primary, Miwa, Haruo, additional, Sugimori, Kazuya, additional, Tozuka, Yuichiro, additional, Ishii, Yuniba, additional, Kameta, Eri, additional, Ishii, Tomohiro, additional, Kaneko, Takashi, additional, Oshima, Takashi, additional, Kokawa, Atsushi, additional, Numata, Kazushi, additional, Kunisaki, Chikara, additional, Tanaka, Katsuaki, additional, and Maeda, Shin, additional

Published
2014
Full Text
View/download PDF

21. Long-term outcomes of endoscopic ultrasound-guided biliary drainage performed with a fully covered self-expandable metallic stent

Author

Sanga, Katsuyuki, primary, Sugimori, Kazuya, additional, Tozuka, Yuichiro, additional, Kuwashima, Hirofumi, additional, Shimizu, Yuro, additional, Kameta, Eri, additional, Miwa, Haruo, additional, Kaneko, Takashi, additional, Kokawa, Atsushi, additional, Numata, Kazushi, additional, Tanaka, Katsuaki, additional, and Maeda, Shin, additional

Published
2014
Full Text
View/download PDF

23. Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer.

Author

Tezuka S, Ueno M, Kobayashi S, Morimoto M, Ohkawa S, Hirotani A, Tozuka Y, Moriya S, Nakamura Y, Miyagi Y, Sugimori M, and Maeda S

Abstract

The platinum-based chemotherapy regimen FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin) is currently used as a standard treatment for patients with unresectable pancreatic cancer. FOLFIRINOX is associated with severe toxicities, including neutropenia, febrile neutropenia, and anorexia; however, there are currently no reliable biomarkers to predict its efficacy and safety. Several studies of patients with various cancers have shown that tumor expression of excision repair cross-complementing (ERCC) proteins and glutathione S-transferase Pi (GSTPi) correlates with the response to platinum-based chemotherapies. Therefore, in this study, we examined the associations between expression of ERCC proteins and GSTPi and the safety and efficacy of FOLFIRINOX in 34 patients with unresectable pancreatic cancer. ERCC1, ERCC2, ERCC4, and GSTPi expression were examined by immunohistochemical staining of tumor specimens and the results were correlated with overall survival, progression-free survival, response rate, disease control rate, and the frequency of grade 3-4 neutropenia and non-hematologic toxicities. We found that ERCC1, ERCC2, ERCC4, and GSTPi were expressed in tumor samples from 64%, 24%, 18%, and 64% of patients, respectively. Notably, there were no statistically significant associations between the expression pattern of any of the proteins and either the clinical outcomes or the frequency of grade 3-4 neutropenia or grade 3-4 anorexia. Collectively, these data indicate that tumor expression of ERCC1, ERCC2, ERCC4, and GSTPi does not predict the safety or efficacy of FOLFIRINOX in patients with pancreatic cancer., Competing Interests: None.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results